Figure 1
Panitumumab-IRDye800 specifically detects EGFR protein expression in human malignant glioma cells. (A) Phase contrast (PH) microscopy images confirmed the healthy growth and expected morphology of six cell lines in vitro before EGFR immunostaining, including human xenograft glioma cell lines (D270, H37, D2159 and U251), positive control (SCC-1) and negative control (293 T). Insets: bright field (BF) microscopic images of individual cell morphology. Fixed cells were immunostained with (B) a commercial EGFR antibody and (C) panitumumab-IRDye800 (pan800). Insets: high magnification views of plasma membrane staining on individual cells. EGFRAb: commercial epidermal growth factor receptor antibody; DAPI: 4′,6-diamidino-2-phenylindole (nuclear stain); FL-C fluorescence confocal microscopy. FL fluorescence microscopy. (D) Mean fluorescence intensity, with standard error of the mean (n = 10), of rabbit-anti-human EGFR antibody and (E) panitumumab-IRDye800, normalized to SCC-1 (as 100%, dotted lines).
